Immune Thrombocytopenia (ITP)

Hematology
5
Pipeline Programs
5
Companies
7
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
2
1
1
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 4 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

argenx
argenxBelgium - Zwijnaarde
1 program
1
Efgartigimod IVPhase 2/31 trial
Active Trials
NCT07194850Recruiting24Est. Oct 2030
Sanofi
SanofiPARIS, France
1 program
1
SAR445088Phase 23 trials
Active Trials
NCT04658472Completed98Est. Oct 2025
NCT04802057Terminated9Est. Mar 2025
NCT04669600Completed12Est. Feb 2023
Climb Bio
Climb BioMA - Wellesley Hills
1 program
1
BudoprutugPhase 1/21 trial
Active Trials
NCT07043946RecruitingEst. Aug 2028
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
PirtobrutinibPhase 1/2Small Molecule1 trial
Active Trials
NCT06721013Recruiting58Est. Feb 2027
H
HutchmedChina - Hong Kong
1 program
1
HMPL-523Phase 11 trial
Active Trials
NCT03951623Completed45Est. Jul 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
argenxEfgartigimod IV
SanofiSAR445088
SanofiSAR445088
Eli Lilly and CompanyPirtobrutinib
Climb BioBudoprutug
SanofiSAR445088
HutchmedHMPL-523

Clinical Trials (7)

Total enrollment: 246 patients across 7 trials

NCT07194850argenxEfgartigimod IV

A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)

Start: Oct 2025Est. completion: Oct 203024 patients
Phase 2/3Recruiting
NCT04658472SanofiSAR445088

Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Start: Apr 2021Est. completion: Oct 202598 patients
Phase 2Completed
NCT04669600SanofiSAR445088

A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)

Start: Feb 2021Est. completion: Feb 202312 patients
Phase 2Completed
NCT06721013Eli Lilly and CompanyPirtobrutinib

A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

Start: Jul 2025Est. completion: Feb 202758 patients
Phase 1/2Recruiting
NCT07043946Climb BioBudoprutug

A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)

Start: Jun 2025Est. completion: Aug 2028
Phase 1/2Recruiting
NCT04802057SanofiSAR445088

Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088

Start: Mar 2021Est. completion: Mar 20259 patients
Phase 1Terminated
NCT03951623HutchmedHMPL-523

The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients

Start: Aug 2019Est. completion: Jul 202245 patients
Phase 1Completed

Related Jobs in Hematology

Délégué Médical LLC/Myélome (H/F) - secteurToulouse

Johnson & Johnson
Issy-les-Moulineaux, France
Yesterday

MSL Hematología L - Sur

Johnson & Johnson
Sevilla, Spain
Yesterday

Senior Manager – Strategy & Business Transformation

Johnson & Johnson
Mumbai, India
Yesterday

Sr. Director Marketing

Genetix Biotherapeutics
Somerville, Massachusetts, United States
4d ago
From $270K/yr

Key Account Specialist Hematology

Johnson & Johnson
Beirut, Lebanon
4d ago

Hematology Field Medical Director, non-MD

Pfizer
Remote
4d ago
$177K - $294K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 actively recruiting trials targeting 246 patients
5 companies competing in this space

Related Indications

Anemia(92)Myelofibrosis(21)Polycythemia Vera(16)Primary Immune Thrombocytopenia(15)Primary Myelofibrosis(14)Immune Thrombocytopenia(12)Thrombocytopenia(11)Beta-Thalassemia(10)Aplastic Anemia(7)Anemia of Chronic Kidney Disease(7)